Sergio Cifuentes Canaval, Medical Oncologist at Las Américas Auna Clinic, shared a post on X about a paper by Aleix Prat et al. published in Clinical Cancer Research:
“HER2DX helps define who responds vs who relapses in HER2+ early breast cancer
Based on histopathologic correlations:
High pCR likelihood (HER2DX pCR-High):
- Higher tumor grade (G3)
- HR-negative tumors
- High Ki-67
- Higher TILs and immune-inflamed phenotype
- More frequent HER2 IHC 3+
Biologically aggressive, but highly chemosensitive
High relapse risk (HER2DX Relapse-High):
- Lower immune infiltration
- Lower TILs
- Less immune-inflamed tumors
- Higher Ki-67 still relevant
Risk driven more by tumor–immune interaction than HER2 level alone
Key insight: pCR likelihood and relapse risk are not mirror images. HER2DX captures two different biological dimensions — response vs long-term control.
This supports treatment personalization beyond anatomy and IHC alone.”
More posts about Breast Cancer.
